glp 1 medicaid Trump won't force to cover GLP-1s for obesity: A few states are doing it anyway Eligible Medicare Part D Members

The Evidence Multiple large cardiovascular outcome trials have demonstrated GLP-1 medications reduce heart attacks, strokes, and cardiovascular death: SUSTAIN-6 (semaglutide): 26% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk

Received: Revised: Accepted: Published: Issue date: DOI:

KPV (derived from -MSH) is the anti-inflammatory arm: in murine models it significantly reduced inflammation and sped recovery[1]

PMID: 41844462 Ahmed F et al

Considering that OSAS patients often present with multiple comorbiditiessuch as hypertension, coronary artery disease, and diabetesfurther large-scale, long-term follow-up studies are needed to clarify tirzepatides safety in multimorbid populations (63, 64)